This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-outlook: Archive
All You Need to Know About Masimo (MASI) Rating Upgrade to Strong Buy
by Zacks Equity Research
Masimo (MASI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MASIPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Want Better Returns? Don't Ignore These 2 Finance Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
WFCPositive Net Change PGRNegative Net Change
earnings-esp earnings-expectations earnings-outlook
Why Investors Need to Take Advantage of These 2 Finance Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
GSPositive Net Change RYPositive Net Change
earnings-esp earnings-expectations earnings-outlook
Lennar (LEN) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Lennar (LEN) delivered earnings and revenue surprises of -5.66% and -2.49%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
LENNegative Net Change KBHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
FedEx (FDX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
FedEx (FDX) delivered earnings and revenue surprises of +4.93% and +2.15%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
FDXNegative Net Change DALNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Research Solutions Inc. (RSSS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Research Solutions (RSSS) delivered earnings and revenue surprises of +75.00% and +0.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
RSSSPositive Net Change IIINPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Scholastic (SCHL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scholastic (SCHL) delivered earnings and revenue surprises of -3.28% and -5.57%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
SCHLPositive Net Change MKCNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Hesai Group Sponsored ADR (HSAI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Hesai Group Sponsored ADR (HSAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
HSAIPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes iRadimed (IRMD) a New Buy Stock
by Zacks Equity Research
iRadimed (IRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IRMDPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Magnite (MGNI) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Magnite (MGNI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MGNINegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Advantest (ATEYY) a New Strong Buy Stock
by Zacks Equity Research
Advantest (ATEYY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ATEYYPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Sumitomo (SSUMY) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Sumitomo (SSUMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SSUMYPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PHATPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Leonardo DRS, Inc. (DRS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Leonardo DRS, Inc. (DRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DRSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
United Bankshares (UBSI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
United Bankshares (UBSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
UBSINegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Yext (YEXT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Yext (YEXT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
YEXTPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Nordea Bank (NRDBY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Nordea Bank (NRDBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NRDBYNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Darden Restaurants (DRI) Misses Q1 Earnings Estimates
by Zacks Equity Research
Darden Restaurants (DRI) delivered earnings and revenue surprises of -1.50% and +0.17%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
DRIPositive Net Change DPZNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
FactSet Research (FDS) Q4 Earnings Lag Estimates
by Zacks Equity Research
FactSet (FDS) delivered earnings and revenue surprises of -2.41% and +0.73%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
FDSPositive Net Change BYRNPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sangoma Technologies Corporation (SANG) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Sangoma Technologies Corporation (SANG) delivered earnings and revenue surprises of +100.00% and +1.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SANGNegative Net Change PAYXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Cracker Barrel Old Country Store (CBRL) Misses Q4 Earnings Estimates
by Zacks Equity Research
Cracker Barrel (CBRL) delivered earnings and revenue surprises of -5.13% and +1.33%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
CBRLPositive Net Change DRIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
NVDA or QBTS: Which is the Better Bet for Quantum Investors in 2025?
by Urmimala Biswas
NVIDIA's hybrid quantum push challenges D-Wave's niche as investors weigh scale against specialization in 2025.
NVDAPositive Net Change QBTSNegative Net Change
artificial-intelligence earnings-outlook earnings-report tech-stocks
All You Need to Know About Algorhythm Holdings, Inc. (RIME) Rating Upgrade to Buy
by Zacks Equity Research
Algorhythm Holdings, Inc. (RIME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RIMEPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
First Bancorp (FBNC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
First Bancorp (FBNC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FBNCNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy
by Zacks Equity Research
Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KZRPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank